Printer Friendly Version  View printer-friendly version
<< Back
Array BioPharma to Host Analyst and Investor Day Featuring Distinguished Clinical Investigators

BOULDER, Colo.--(BUSINESS WIRE)--Dec. 1, 2011-- Array BioPharma Inc. (NASDAQ: ARRY) today announced that it will host an Analyst and Investor Day on Friday, December 16, 2011, from 8:30 a.m. to 11:30 a.m. EST in New York City. Array will provide updates on its clinical programs in cancer and inflammation.

The meeting will feature a group of distinguished independent experts who will share their perspectives on the general landscape of cancer treatments in development and Array’s drug candidates.

A noted medical oncologist will provide an update on MEK inhibitors as cancer therapeutics including Array’s partnered drugs, selumetinib and MEK162:

Jeffrey Infante, M.D.
Director, Drug Development Program
Sarah Cannon Research Institute

And leading hematologists will discuss data presented on ARRY-520, a KSP inhibitor, and ARRY-614, a dual p38/Tie2 inhibitor, at the American Society of Hematology Meeting earlier that week:

Robert Orlowski, M.D., Ph.D.
Professor, Department of Lymphoma/Myeloma
University of Texas MD Anderson Cancer Center

Guillermo Garcia-Manero, M.D.
Professor of Medicine and Chief, Section of Myelodysplastic Syndrome
University of Texas MD Anderson Cancer Center

The Analyst and Investor Day is open to members of the professional investment community. For information on attending the event, please contact Tricia Haugeto at

The live webcast of the meeting, including slides, will also be available in the Investor Relations section of Array’s website:

Please log in approximately 10 minutes prior to the presentation to ensure a timely connection. An archived version will also be available on the Company’s website for a limited time after the event.

About Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small-molecule drugs to treat patients afflicted with cancer and inflammatory diseases. Our proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target proteins and are aimed at significant unmet medical needs. For more information on Array, please go to

Source: Array BioPharma Inc.

Array BioPharma Inc.
Tricia Haugeto, 303-386-1193

ShareThis Copy and Paste